罗格列酮对DM2患者血清MMP-9和TIMP-1影响的研究

The Effects of Rosiglitazone on the Serum MMP-9 and TIMP-1 in Type 2 Diabetic

目的:探讨2型糖尿病(DM2)患者血清基质金属蛋白酶-9(MMP-9)和组织抑制因子1(TIMP-1)的变化,以及罗格列酮治疗对其的影响。方法:临床观察采用随机对照方法,选择100例初诊DM2患者和50例正常人对照。将100例DM2患者分为A组和B组,A组常规降糖治疗,B组在常规治疗基础上加服罗格列酮,16周后测定患者治疗前后血清MMP-9及TIMP-1水平。结果:DM2患者血清MMP-9、TIMP-1及MMP-9/TIMP-1水平较正常对照组显著升高(P<0.01);B组治疗前后血清MMP-9、TIMP-1及MMP-9/TIMP-1显著降低(P<0.01),A组治疗前后血清MMP-9、TIMP-1及MMP-9/TIMP-1差异无统计学意义(P>0.05);且MMP-9与TIMP-1之间,MMP-9/TIMP-1与MMP-9、TIMP-1之间均呈正相关。结论:血清MMP-9与TIMP-1可能与DM2发生、发展有关,罗格列酮能显著降低DM2患者MMP-9与TIMP-1水平,纠正MMP-9/TIMP-1比值,以期达到早期诊治,防止DM2大血管病变的目的。

Objective To explore the change of rosiglitazone on type 2 diabetic patients and the impact on the expressions of MMP-9 and TIMP-1.Methods The clinica1 observation using randomized controlled method,100 patients with DM2 were selected in our study,and 50 healthy adults served as normal control.100 cases of type 2 diabetics were divided into A and B group.The group A was treated only with conventional therapy.The group B was given rosiglitazone besides conventional therapy.And the concentrations of MMP-9 and TIMP-1 in serum were detected before and after therapy.Results The DM2 diabetics group serum MMP-9,TIMP-1 and MMP-9/TIMP-1 levels were obvious higher than the healthy control group（P0.01）;The serum levels of MMP-9,TIMP-1,MMP-9/TIMP-1 on B group after treatment were apparently lower than those before treatment and A group after treatment（P0.01）,while the serum levels of MMP-9,TIMP-1,MMP-9/TIMP-1 on B group after treatment were no significantly difference（P0.05）.There was a positive correlation between MMP-9/TIMP-1 and expression level of MMP-9 and TIMP-1 in DM2 diabetics（r=0.631,r=0.558,all P0.01）,the serum level of MMP-9 was also positive correlation with TIMP-1（r=0.717,P0.01）.Conclusion There may be a relevance between serum MMP-9,TIMP-1 and the incidence of DM2.Rosiglitazone can significantly reduce the levels of MMP-9 and TIMP-1 in DM2 diabetics,and corrective MMP-9/TIMP-1 ratio,in order to achieve the purpose of early diagnosis and early prevention of DM2 macroangiopathy.